Healthcare
Live Price
Offline$20.88
+5.19% today
1Y Change
-66.64%
Window
Jun 30, 2025 → Jun 18, 2026
Coverage: 244 bars · Jun 30, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Doximity, Inc. (DOCS) is a Healthcare stock with a market cap of $4.84B and listed on NYSE. The stock last traded around $20.88 and down 66.6% across the available one-year price window (Jun 30, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +20.0%, EPS growth of +52.6%, a dividend yield of 0.0%. What stands out right now is revenue +20.0%, EPS +52.6%, free cash flow +49.6% with operating margin 37.4% and ROIC 20.5%. Valuation sits in the middle of the pack at P/E 20.2 and price/sales 7.6. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines DOCS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
DOCS is 87.51 pts behind over the shared 1Y window.
DOCS had 66.89 pts deeper max drawdown than SPY.
DOCS beat SPY in 0 of 2 calendar years shown and trailed in 2.
DOCS
-66.64%
Normalized return
SPY
+20.86%
S&P 500
Excess Return
-87.51 pts
Relative to SPY
DOCS Max Drawdown
-76.03%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for DOCS and SPY.
| Year | DOCS | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | -52.74% | +6.71% | -59.44 pts | SPY |
| 2025 | -27.32% | +11.19% | -38.52 pts | SPY |
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$206.9M
-39.8% YoY
FY Net Income
$50.2M
-67.6% YoY
Free Cash Flow
$78.4M
-35.2% YoY
Revenue Growth
+20.0%
EPS Growth
+52.6%
Gross Margin
89.7%
Net Margin
37.5%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 570M | 475M | 419M | 344M | 207M |
| Gross Profit | 515M | 425M | 366M | 304M | 176M |
| Operating Income | 228M | 164M | 125M | 114M | 53M |
| EBITDA | 241M | 182M | 135M | 119M | 57M |
| Net Income | 223M | 148M | 113M | 155M | 50M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 210M | 97M | 158M | 113M | 66M |
| Total Assets | 1.3B | 1.1B | 1.1B | 991M | 252M |
| Total Liabilities | 182M | 178M | 171M | 113M | 185M |
| Shareholder Equity | 1.1B | 901M | 966M | 879M | 67M |
| Total Debt | 12M | 15M | 16M | 1M | 1M |
| Net Debt | -197M | -82M | -142M | -112M | -65M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
83M
-34.4% YoY
Capital Expenditures
5M
+19.1% YoY
Free Cash Flow
78M
-35.2% YoY
Key ratios
Gross Margin
89.7%
Operating Margin
37.4%
Net Margin
37.5%
ROE
22.9%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.